IRIS
AVENALI, MICOL
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.799
AS - Asia 1.627
EU - Europa 1.430
SA - Sud America 325
Continente sconosciuto - Info sul continente non disponibili 114
AF - Africa 88
OC - Oceania 6
Totale 6.389
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.651
CN - Cina 501
IT - Italia 489
SG - Singapore 422
BR - Brasile 245
IE - Irlanda 238
HK - Hong Kong 223
RU - Federazione Russa 189
VN - Vietnam 173
DE - Germania 141
BD - Bangladesh 98
FR - Francia 92
FI - Finlandia 72
GB - Regno Unito 64
CA - Canada 62
IN - India 53
ZA - Sudafrica 53
NL - Olanda 26
MX - Messico 24
AR - Argentina 22
ID - Indonesia 20
JP - Giappone 20
CO - Colombia 17
PL - Polonia 17
IQ - Iraq 15
PK - Pakistan 13
CR - Costa Rica 12
SE - Svezia 12
UA - Ucraina 12
CZ - Repubblica Ceca 11
TR - Turchia 11
ES - Italia 10
GT - Guatemala 10
MA - Marocco 10
EC - Ecuador 9
VE - Venezuela 9
AT - Austria 8
JO - Giordania 8
MY - Malesia 8
PH - Filippine 8
BE - Belgio 7
AL - Albania 6
CL - Cile 6
IL - Israele 6
KG - Kirghizistan 6
NI - Nicaragua 6
PY - Paraguay 6
UZ - Uzbekistan 6
AU - Australia 5
EE - Estonia 5
GP - Guadalupe 5
HN - Honduras 5
KR - Corea 5
MO - Macao, regione amministrativa speciale della Cina 5
TT - Trinidad e Tobago 5
BO - Bolivia 4
CH - Svizzera 4
EG - Egitto 4
JM - Giamaica 4
KE - Kenya 4
RO - Romania 4
RS - Serbia 4
SA - Arabia Saudita 4
SC - Seychelles 4
UY - Uruguay 4
BB - Barbados 3
CI - Costa d'Avorio 3
CW - ???statistics.table.value.countryCode.CW??? 3
KZ - Kazakistan 3
LT - Lituania 3
PE - Perù 3
PR - Porto Rico 3
SI - Slovenia 3
SV - El Salvador 3
TN - Tunisia 3
AM - Armenia 2
AZ - Azerbaigian 2
DK - Danimarca 2
DZ - Algeria 2
GR - Grecia 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MQ - Martinica 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BM - Bermuda 1
BW - Botswana 1
BY - Bielorussia 1
DJ - Gibuti 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
HR - Croazia 1
IR - Iran 1
KH - Cambogia 1
KW - Kuwait 1
Totale 6.268
Salva come PNG Salva come JPEG
Città #
San Jose 336
Dublin 227
Singapore 227
Hong Kong 220
Chandler 214
Council Bluffs 196
Ashburn 194
Dallas 187
Beijing 130
Los Angeles 85
Boardman 81
Milan 77
Rome 71
Santa Clara 61
Ho Chi Minh City 58
New York 55
Lauterbourg 52
Helsinki 48
Johannesburg 47
Munich 41
Hanoi 39
Shanghai 38
Moscow 36
Princeton 35
Lawrence 32
Nanjing 30
Wilmington 30
Columbus 29
Medford 29
Naples 29
Redondo Beach 29
Buffalo 28
São Paulo 27
Orem 24
Frankfurt am Main 20
North Bergen 19
Phoenix 19
Turku 18
Hebei 17
The Dalles 17
Tokyo 17
Warsaw 17
Brooklyn 15
Florence 15
Jacksonville 15
Montreal 15
Nanchang 15
Nuremberg 15
Chennai 14
Turin 14
Amsterdam 13
Hangzhou 13
London 12
Seattle 12
Cagliari 11
Chicago 11
Falkenstein 11
Houston 11
Pavia 11
Shenyang 11
Toronto 11
Düsseldorf 10
Fairfield 10
Figino 10
Haiphong 10
Mexico City 10
Rio de Janeiro 10
Boston 9
Changsha 9
Denver 9
Amman 8
Atlanta 8
Guatemala City 8
Norwalk 8
Stockholm 8
Tianjin 8
Ann Arbor 7
Belo Horizonte 7
Brno 7
Da Nang 7
Guangzhou 7
Menlo Park 7
San Francisco 7
San José 7
Baghdad 6
Bishkek 6
Biên Hòa 6
Charlotte 6
Dhaka 6
Les Paris 6
Managua 6
Medellín 6
Poplar 6
Pune 6
Queens 6
Tashkent 6
Washington 6
Bakersfield 5
Bari 5
Bogotá 5
Totale 3.715
Salva come PNG Salva come JPEG
Nome #
CLINICAL AND BIOCHEMICAL SIGNATURES OF GBA-RELATED PARKINSON DISEASE 184
Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism 166
Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy 163
A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value 146
What is the role of the placebo effect for pain relief in neurorehabilitation? Clinical implications from the Italian consensus conference on pain in neurorehabilitation 144
Consensus on the treatment of dysphagia in Parkinson's disease 141
Body Weight Support Combined With Treadmill in the Rehabilitation of Parkinsonian Gait: A Review of Literature and New Data From a Controlled Study 137
Time for a consensus conference on pain in neurorehabilitation 137
KCTD17-related myoclonus-dystonia syndrome: clinical and electrophysiological findings of a patient with atypical late onset 136
Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study 130
Reproducibility and reaction time of swallowing as markers of dysphagia in parkinsonian syndromes 126
GBA-Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort 125
Extracellular Vesicles Derived From Plasma of Patients With Neurodegenerative Disease Have Common Transcriptomic Profiling 124
Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study. 122
Different miRNA profiles in plasma derived small and large extracellular vesicles of neurodegenerative disease patients. 120
Blood D-serine levels correlate with aging and dopaminergic treatment in Parkinson's disease 119
Botulinum toxin for chronic migraine: Clinical trials and technical aspects 117
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol 115
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations 115
Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project 114
The Effects of Intensive Neurorehabilitation on Sequence Effect in Parkinson's Disease Patients With and Without Freezing of Gait 114
Outcomes of a computer-based cognitive training (CoRe) in early phases of cognitive decline: a data-driven cluster analysis 111
Cost of Chronic and Episodic Migraine: a pilot study from a tertiary headache centre in northern Italy 108
Clinical and Electrophysiological Outcome Measures of Patients With Post-Infectious Neurological Syndromes Related to COVID-19 Treated With Intensive Neurorehabilitation 107
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting 104
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 104
Harmonic ratio is the most responsive trunk-acceleration derived gait index to rehabilitation in people with Parkinson’s disease at moderate disease stages 101
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease 101
Non-Invasive Neuromodulation in the Rehabilitation of Pisa Syndrome in Parkinson's Disease: A Randomized Controlled Trial 100
The role of stroke-induced immunosuppression as a predictor of functional outcome in the neurorehabilitation setting 94
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 91
Are patients with GBA-Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort 86
Serum dysregulation of serine and glycine metabolism as predictive biomarker for cognitive decline in frail elderly subjects 86
A narrative review on the role and main findings of the Videofluoroscopic Study of Swallowing in Parkison's disease 85
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort 85
Apomorphine Subcutaneous Infusion Likely Induced Acute Thrombocytopenia in a Patient with Parkinson's Disease and Motor Fluctuations 80
Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology: Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation 80
Pearls & Oy-sters: Marionette Walk in Parkinson Disease 79
Bilateral Dentate Nuclei Hyperintensities and Response to 4-Aminopyridine in a Patient With Childhood-Onset GAA- FGF14 -Related Ataxia 77
From DYMUS to DYPARK: Validation of a Screening Questionnaire for Dysphagia in Parkinson’s Disease 77
Exploring the neural and behavioral correlates of cognitive telerehabilitation in mild cognitive impairment with three distinct approaches 76
Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease? 76
Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: A 6-year longitudinal study 71
Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) 69
Outcomes of a computer-based cognitive training (CoRe) in early phases of cognitive decline: a data-driven cluster analysis 67
CSF d18:1 sphingolipid species in Parkinson disease and dementia with Lewy bodies with and without GBA1 variants 67
Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach 66
Psychological treatments and psychotherapies in the neurorehabilitation of pain: Evidences and recommendations from the italian consensus conference on pain in neurorehabilitation 64
Functional Study of SNCA p.V15A Variant: Further Linking α-Synuclein and Glucocerebrosidase 63
Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study 62
Parkinson disease following COVID-19: Report of six cases 62
Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells 62
Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-up in Parkinson disease patients with mild cognitive impairment: a randomized controlled trial 62
The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease 61
LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients 61
Proprioceptive Focal Stimulation (Equistasi®) May Improve the Quality of Gait in Middle-Moderate Parkinson's Disease Patients. Double-Blind, Double-Dummy, Randomized, Crossover, Italian Multicentric Study 59
Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale 57
Psychological, clinical, and therapeutic predictors of the outcome of detoxification in a large clinical population of medication-overuse headache: A six-month follow-up of the COMOESTAS Project 56
Plasma extracellular vesicles and phosphorylated tau 181 as early biomarkers of cognitive impairment in Alzheimer’s dementia 54
Reply to: “Increased alpha-Synuclein Level in CD45+ Blood Cells in Asymptomatic Carriers of GBA Mutations” 53
Long-Term Motor and Cognitive Outcome of Deep Brain Stimulation in Patients With Parkinson Disease With a GBA1 Pathogenic Variant 51
Pain in focal dystonias - A focused review to address an important component of the disease 40
Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease 38
RAB32 mutation in Parkinson's disease [2] 37
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study 37
The interplay between GBA1 status and age of onset on cognitive, motor and non-motor outcomes in Parkinson's disease: multicenter cross-sectional study 30
null 30
Clustering Algorithm Reveals Dopamine-Motor Mismatch in Cognitively Preserved Parkinson's Disease 28
RAB32-Linked Parkinson's Disease: Deep Phenotyping, MDSGene Literature Review, and Application of SynNeurGe Criteria 27
Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review 27
1H-NMR-based metabolomics identifies disrupted betaine metabolism as distinct serum signature of pre-frailty 26
Microbiome signature of Parkinson's disease in healthy and genetically at-risk individuals 25
Initiating foslevodopa infusion in Parkinson disease: a pragmatic study 20
Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials 20
Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation 18
Domain-driven verbal and non-verbal dissociations in cognition and social cognition in Parkinson’s disease 17
Asymmetric Parietal Cortical Atrophy in a Patient with RAB39B-Associated Parkinsonism 15
LONG-NEXT: A new accurate and efficient NGS-based method for GBA1 analysis in Parkinson disease 14
Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson’s disease patients 13
The treatment of axial and foot dystonia 12
Male sex accelerates cognitive decline in GBA1 Parkinson’s disease 11
Combined assessment of blood glucocerebrosidase activity and α-synuclein levels in GBA1 mutation carriers: A novel potential biomarker 11
Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies 9
Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa–Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, “Real-World” Study. The EPIC Study 8
Loss of serotonergic function in carriers of PRKN mutations: a [11C]DASB PET study 6
Totale 6.389
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.554
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.554
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022166 0 0 0 0 9 13 3 13 11 1 20 96
2022/2023576 59 54 5 69 33 46 1 22 261 3 15 8
2023/2024360 37 48 8 22 11 70 29 24 2 11 50 48
2024/20251.144 39 60 21 21 44 116 128 63 260 61 124 207
2025/20262.687 196 193 279 267 288 94 442 139 273 208 191 117
2026/20271.192 104 251 217 407 213 0 0 0 0 0 0 0
Totale 6.389